Laura J. Esserman

MD MBA

Director, Carol Franc Buck Breast Care Center

Dr. Laura Esserman, a nationally known breast surgeon, directs the UCSF Carol Franc Buck Breast Care Center at the Mount Zion campus. Her work is devoted to developing new, more effective ways to care for and empower breast cancer patients during treatment. She tailors treatments for individual patients using biology, personal preference and constant feedback regarding outcomes of care.

Esserman earned her undergraduate degree at Harvard University and completed her medical and surgical training at Stanford University. She completed a postdoctoral fellowship in breast oncology at Stanford and later earned a master's degree from the Stanford Graduate School of Business. She joined UCSF Medical Center in 1993.

  • Education

    Stanford University, 1983

  • Residencies

    Stanford University, General Surgery, 1991

  • Board Certifications

    Surgery, American Board of Surgery

  • Academic Title

    Professor

  • Languages

    Spanish

Conditions I specialize in

Where I see patients (1)

    My reviews

    4.9

    Overall Experience
    94 Ratings
    Explained things in a way that was easy to understand
    93 Ratings
    Did the doctor pay attention to your concerns
    94 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    91 Ratings
    Knew the important information about your medical history
    93 Ratings
    The provider showed respect for what you had to say
    93 Ratings
    The provider spent enough time with me
    94 Ratings
    Read all reviews About our process

    Selected research

    Decorative Caduceus

    Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

    Change in fibroglandular volume assessed on 3-D digital mammogram by Volpara software.

    Recruiting

    Decorative Caduceus

    Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

    Proportion of cancers diagnosed at Stage IIB or higher

    Recruiting

    Decorative Caduceus

    I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

    Time to achieve durable change in COVID-19 to ordinal level 4 or less for at least 48 hours

    Recruiting

    Decorative Caduceus

    Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)

    To determine the maximum tolerated dose (MTD), and recommended dose for subsequent expansion cohort, of intralesionally administered pembrolizumab in patients with ductal carcinoma in situ (DCIS) of the breast.

    Recruiting

    My work

    Doctors debate whether to stop calling low-risk tumors 'cancer'

    Contact me

    Providers on my team

    Share